Is MOTS-c Legal in Wisconsin? How to Access It Legally

What Is MOTS-c and Why Does Its Legal Status Matter?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid mitochondria-derived peptide first characterized by Lee and colleagues in a 2015 Cell paper. [1] The peptide is encoded by the mitochondrial genome and appears to regulate metabolic processes, including insulin sensitivity and fatty acid oxidation in skeletal muscle. Early animal data were striking enough to generate significant clinical interest.

Because MOTS-c is not an FDA-approved drug, anyone who wants to use it therapeutically in a human being in Wisconsin must understand a multi-layered legal framework. That framework includes federal drug law, FDA compounding regulations, and Wisconsin's own pharmacy practice act. Getting any one layer wrong creates legal and safety risk for both the prescriber and the patient.

Why Patients Are Asking About MOTS-c Now

Interest in this peptide has grown sharply since a 2021 paper in Nature Communications showed that circulating MOTS-c levels decline with age in humans and that exogenous MOTS-c administration improved physical performance in aged male mice. [2] That kind of headline-grabbing finding pushes patients toward direct-to-consumer peptide vendors before the regulatory picture is clear.

The Core Legal Question

The legal question is not simply "is this molecule a controlled substance." It is more nuanced: Can a pharmacy legally compound MOTS-c for human use? Can a physician prescribe it? Those answers depend entirely on FDA's stance on MOTS-c as a bulk drug substance, which is discussed in detail below.

Federal Law: The Foundation of MOTS-c's Legal Status

Wisconsin has not enacted any state statute specifically addressing MOTS-c. That means federal law is the primary governing framework.

The Federal Food, Drug, and Cosmetic Act

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a substance intended for use in a human being is a "drug" if it is intended to diagnose, cure, treat, mitigate, or prevent disease, or to affect the structure or function of the body. [3] MOTS-c clearly falls into that category when marketed or prescribed for therapeutic purposes. Selling it without FDA approval, outside the narrow exceptions for compounding, is a federal violation.

503A Compounding Pharmacies

Section 503A of the FD&C Act governs traditional compounding pharmacies that prepare individualized prescriptions for specific patients. A 503A pharmacy may use a bulk drug substance only if it meets one of three conditions:

1. The substance appears on the FDA's "503A bulks list" (officially the list of bulk drug substances that may be used in compounding under section 503A).
2. A United States Pharmacopeia (USP) or National Formulary (NF) monograph exists for the substance.
3. The substance is a component of an FDA-approved drug.

MOTS-c satisfies none of these three conditions as of the date of this article's last review. The FDA's current 503A bulks list does not include MOTS-c. [4] A nomination for MOTS-c was submitted to the FDA for evaluation, but the agency has not placed it on the affirmative "Category 1" list of substances that are permissible for 503A compounding. That absence means a 503A pharmacy that compounds MOTS-c for patient-specific prescriptions is operating outside the legal safe harbor and risks FDA enforcement action.

503B Outsourcing Facilities

Section 503B facilities are larger-scale compounders that produce drugs without patient-specific prescriptions but must register with the FDA and meet current Good Manufacturing Practice (cGMP) standards. The same bulk substance restrictions apply. MOTS-c is not on the 503B bulks list either. [4] A 503B facility cannot legally produce MOTS-c for human use under current federal rules.

FDA Enforcement Actions on Peptides

The FDA has demonstrated it will act on peptide compounding violations. In 2023 and 2024, the agency issued warning letters to compounding pharmacies citing unauthorized use of peptides including BPC-157, TB-500, and related substances. [5] MOTS-c has not yet been the subject of a specific published warning letter as of January 2025, but it falls under the same regulatory logic. Pharmacies that ignore the bulks list framework face potential injunctions, seizures, and criminal referrals.

Wisconsin State Law: What the State Adds (and Does Not Add)

Wisconsin does not have a specific statute that mentions MOTS-c by name. State law operates on top of the federal baseline rather than replacing it.

Wisconsin Pharmacy Practice Act

The Wisconsin Pharmacy Examining Board, operating under Wis. Stat. Chapter 450, licenses pharmacists and pharmacies in the state. [6] Under those rules, a Wisconsin-licensed pharmacy must comply with all applicable federal law, including the FD&C Act and FDA compounding regulations. A Wisconsin pharmacy cannot legally do something that federal law prohibits. The converse is also true: if a substance were to receive federal clearance for 503A compounding, Wisconsin pharmacies could compound it without any additional state-level permission (absent a state-specific restriction, which does not currently exist for MOTS-c).

Wisconsin Medical Practice Act

Physicians licensed in Wisconsin under Wis. Stat. Chapter 448 have broad authority to prescribe drugs and direct patient care. [7] The doctrine of "off-label prescribing" is well-established and allows physicians to prescribe FDA-approved drugs for uses not listed in official labeling. That doctrine does not, however, extend to prescribing an unapproved bulk substance that a compounding pharmacy cannot legally dispense. A Wisconsin physician can write a prescription for MOTS-c, but a compliant pharmacy has no legal pathway to fill it under current federal rules.

Wisconsin Department of Safety and Professional Services

The Wisconsin DSPS oversees licensed health professionals. Prescribing substances that cannot be legally compounded could constitute unprofessional conduct under Wis. Admin. Code Chapter Med 10. Clinicians should document their rationale carefully and consult their malpractice carrier before prescribing any peptide in a federal regulatory gray zone.

The Research Chemical Pathway: Legal But Narrow

One path that is genuinely legal is purchasing MOTS-c as a research chemical for non-human, in-vitro laboratory use.

What "Research Use Only" Actually Means

Vendors who sell MOTS-c labeled "research use only" (RUO) or "not for human use" are operating under a different part of federal law. Selling a chemical compound for legitimate laboratory research is not automatically a drug violation, provided the seller does not make therapeutic claims and the buyer does not use the substance in or on a human being. [3]

The legal line breaks the moment the compound is administered to a person. A patient who buys RUO MOTS-c and self-injects it is using an unapproved drug outside any medical supervision. That is not a crime for the individual patient under current federal enforcement priorities, but it creates serious safety concerns (sterility, dosing accuracy, unknown contaminants) and no legal protection.

No Physician Can Authorize RUO Use

A physician prescription does not transform an RUO product into a legal pharmaceutical. The RUO designation specifically means the product has not been manufactured to pharmaceutical quality standards. No Wisconsin-licensed provider can legitimately prescribe an RUO product for patient self-administration and remain within the boundaries of standard medical practice.

Telehealth Access in Wisconsin: What Is and Is Not Possible

Wisconsin allows telehealth practice under Wis. Stat. 448.9785, and the state has adopted a relatively permissive telehealth framework. [7] A Wisconsin-licensed provider can evaluate and prescribe for a patient via synchronous video or audio without a prior in-person visit for most conditions.

What Telehealth Changes

Telehealth changes access and convenience. It does not change the underlying pharmacy law. A telehealth provider in Wisconsin who prescribes MOTS-c faces the same dispensing wall as an in-person provider: there is no compliant 503A or 503B pharmacy that can legally fill the script under current FDA rules.

Some telehealth platforms have continued to offer certain peptides by routing prescriptions to compounding pharmacies that accept the legal risk. Patients should ask any telehealth provider exactly which FDA-registered pharmacy would fill the prescription and whether that pharmacy's use of MOTS-c as a bulk substance has received any FDA clearance.

Alternatives a Telehealth Provider Can Legally Prescribe

A Wisconsin telehealth provider evaluating a patient interested in metabolic optimization or longevity-focused therapy has several FDA-approved or clearly legal options:

• Metformin (FDA-approved, 500 mg to 2,000 mg/day, widely used off-label for longevity protocols)
• Semaglutide 2.4 mg weekly (FDA-approved under brand name Wegovy for weight management; STEP-1, N=1,961, showed 14.9% mean body weight reduction at 68 weeks vs. 2.4% with placebo) [8]
• Tirzepatide 15 mg weekly (FDA-approved under brand name Zepbound; SURMOUNT-1, N=2,539, showed up to 20.9% mean weight loss at 72 weeks) [9]
• Tesamorelin (FDA-approved for HIV-associated lipodystrophy, with compounding permitted under specific conditions)

These are not substitutes for MOTS-c specifically, but they represent the legal field for metabolic and body-composition treatment in Wisconsin right now.

The Science Behind MOTS-c: Why the Interest Is Real

The legal constraints on MOTS-c are not because the science is weak. The regulatory gap exists because the approval process takes years and no pharmaceutical company has yet sponsored a New Drug Application for MOTS-c.

Mechanism of Action

MOTS-c activates AMP-activated protein kinase (AMPK) in skeletal muscle, a pathway that also responds to metformin and exercise. [1] AMPK activation improves glucose uptake, reduces lipid accumulation, and supports mitochondrial biogenesis. The peptide also appears to translocate to the cell nucleus under stress conditions, where it modulates gene expression related to oxidative stress response.

Human Data: Limited but Emerging

The 2021 Nature Communications study by Reynolds and colleagues measured serum MOTS-c concentrations in 112 healthy adults across age decades and found a statistically significant decline (P<0.001) in MOTS-c levels beginning in the fourth decade of life, with the sharpest drop occurring between ages 40 and 60. [2] That correlation with aging does not prove that supplementing MOTS-c reverses aging, but it provides a biological rationale for further study.

No Phase 2 or Phase 3 randomized controlled trials in humans have been published as of January 2025. The absence of human trial data is itself a reason the FDA has not cleared MOTS-c for compounding: the agency needs a safety and efficacy record before placing a substance on the affirmative bulks list.

Exercise Mimetic Research

A 2019 study published in Cell Metabolism (Lee et al., N=8 subjects per group in the mouse arm, with a small human observational component) found that MOTS-c plasma levels rise acutely after high-intensity exercise. [10] The authors described the peptide as an "exercise-induced mitokine," a phrase that has driven much of the popular press coverage. The human observational portion was not a clinical trial and cannot establish dosing or safety parameters for therapeutic use.

A Practical Decision Framework for Wisconsin Patients and Providers

The following framework helps clinicians and patients think through the MOTS-c question systematically, given the current regulatory environment.

Step 1: Confirm the Current FDA Bulks List Status

Before any prescribing decision, the provider should verify whether MOTS-c has moved to the Category 1 affirmative list on the FDA's 503A bulks page. [4] That list is updated periodically and may change after this article's publication date.

Step 2: Identify the Dispensing Pharmacy

If a prescriber intends to prescribe MOTS-c, the prescriber must identify which specific pharmacy would fill the prescription, confirm that pharmacy's registration status with the FDA, and document how the pharmacy justifies its use of MOTS-c as a bulk substance. A pharmacy that cannot provide that documentation should not be used.

Step 3: Evaluate Evidence-Supported Alternatives

Given the thin human trial data and the current legal constraints, providers should discuss whether FDA-approved agents targeting the same metabolic pathways (AMPK activation, mitochondrial function, insulin sensitivity) would meet the patient's therapeutic goals. Metformin at 500 to 1,000 mg twice daily, for example, is a low-cost, extensively studied AMPK activator with a 60-year safety record.

Step 4: Document Informed Consent Thoroughly

If a prescriber proceeds with MOTS-c through a pharmacy that accepts the regulatory risk, the informed consent process must cover the absence of FDA approval, the lack of Phase 2 or Phase 3 human trial data, the uncertainty about dosing, and the potential for compounding quality variation. The American Society of Anesthesiologists' compounding guidance and the Endocrine Society's position on unapproved hormone therapies both stress that patients must receive this level of disclosure. [11]

Step 5: Monitor and Report Adverse Events

Any adverse event following MOTS-c administration should be reported to FDA MedWatch. [12] Voluntary reporting from compounding settings is a primary source of post-market safety data for substances that lack formal approval.

What Legitimate Access Could Look Like in the Future

MOTS-c is not permanently locked out of the legal compounding pathway. The FDA's 503A bulks process is designed to evaluate nominated substances and either approve or deny them based on safety and efficacy data.

If a sponsor submits adequate preclinical and Phase 1 safety data supporting MOTS-c, the FDA could place it on the affirmative Category 1 list. At that point, 503A pharmacies in Wisconsin could compound MOTS-c for patient-specific prescriptions with a valid prescription from a licensed provider. The timeline for that outcome is unknown and depends entirely on whether a commercial sponsor pursues the nomination.

The Peptide Society and individual researchers have advocated for an expedited review pathway for mitochondria-derived peptides given their potential in age-related metabolic disease. Whether the FDA adopts such a pathway is a legislative and regulatory question, not a scientific one.